Nurix Therapeutics (NASDAQ: NRIX) reported a sale of 14,261 common shares by Chief Legal Officer Christine Ring on February 9, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares changed hands at a weighted average price of $16.6621, producing total proceeds of $237,618. The sale price for individual transactions ranged from $16.37 to $16.88.
After the disposition, Ring retains direct ownership of 42,749 shares of Nurix stock. The transaction was carried out under a pre-established Rule 10b5-1 trading plan, a mechanism that allows insiders to execute trades according to a pre-set schedule.
Market data noted within the filing context places Nurix’s enterprise value at approximately $1.72 billion. InvestingPro analysis cited in connection with the filing highlights that while the company shows a balance sheet with more cash than debt, it is drawing down its cash reserves at a measured but notable pace.
Analysts following Nurix remain broadly constructive. A consensus rating of "Strong Buy" is reported, and several firms have moved to increase their price targets following corporate and clinical updates.
Stifel raised its price target to $35, underlining the importance of the 2026 timeline for Nurix’s bexobrutideg program as it moves through key registrational trials. Piper Sandler also lifted its target to $35 after Nurix released its fourth-quarter 2025 earnings report, which included accelerated plans for the bexobrutideg treatment. H.C. Wainwright raised its target to $32 after the company posted a net loss of $0.82 per share, a result described as slightly better than that firm’s estimate.
RBC Capital adjusted its target to $30 while maintaining an Outperform rating, noting that updates such as ASH data and study design amendments had been previously disclosed. BTIG reiterated a Buy rating with a $30 target, pointing to Nurix’s solid cash position and progress across pivotal programs. Analysts highlighted the company’s work on therapies for chronic lymphocytic leukemia and small lymphocytic lymphoma as central to their positive stances.
InvestingPro’s valuation take, as referenced alongside the transaction, indicates that the stock is trading a bit below its calculated Fair Value. For investors or subscribers seeking a deeper look, InvestingPro makes additional analytical material and ProTips available for those evaluating Nurix’s financial trajectory and development progress.
Overall, the insider sale represents a routine disclosure amid an active period of analyst engagement and clinical development milestones for Nurix. The combination of insider trading activity, evolving analyst price targets, and commentary on the company’s cash consumption frames the near-term investor narrative for NRIX.